We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0H1P market cap is 197.14M. The company's latest EPS is SEK -0.4119 and P/E is -4.61.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Revenue | 50.85M | 107.58M | 94.28M | 104.51M | 84.08M |
| Operating Income | -15.06M | 6.92M | 12.57M | 6.66M | -16.4M |
| Net Income | -16.01M | 11.33M | 9.21M | 5.89M | -18.25M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Total Assets | 34.94M | 66.55M | 72.46M | 89.75M | 72.71M |
| Total Liabilities | 26.19M | 46.87M | 43.02M | 54.32M | 55.4M |
| Total Equity | 8.75M | 19.68M | 29.44M | 35.44M | 17.31M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | SEK (SEK) | |
| Operating | -3.51M | 18.63M | 7.77M | -6.88M | -303k |
| Investing | -609k | -2.73M | -6.7M | -6.15M | -14.76M |
| Financing | 9.44M | -2.17M | -1.24M | -1.49M | 8.73M |
| Market Cap | 197.14M |
| Price to Earnings Ratio | -4.61 |
| Price to Sales Ratio | 1 |
| Price to Cash Ratio | 65.29 |
| Price to Book Ratio | 4.86 |
| Dividend Yield | - |
| Shares Outstanding | 44.3M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Ortivus Ab |
| Address |
karlsrovagen 2d danderyd 182 17 |
| Website | https://www.ortivus.com |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
